10x Genomics won a $4.8 million patent infringement lawsuit against Qiagen subsidiary Parse Bioscien

BioLife Solutions (NASDAQ: BLFS - Get Free Report) and Qiagen (NYSE: QGEN - Get Free Report) are bot

10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences PR Newswire PLEASANTON, Cali

Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidi

Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity chall

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Fr

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has b

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Stan

QIAstat-Dx BCID GPF Plus AMR Panel detects 20 pathogen targets and 10 antimicrobial resistance marke

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfu

Citigroup analyst Brendan Digan maintains Qiagen (NYSE:QGEN) with a Neutral and raises the price

Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financ

Qiagen NYSE: QGEN reported second-quarter 2026 results above its prior outlook, with net sales of $5

Barclays analyst Luke Sergott maintains Qiagen (NYSE:QGEN) with a Equal-Weight and raises the pri

JP Morgan analyst Casey Woodring maintains Qiagen (NYSE:QGEN) with a Overweight and raises the pr

Qiagen (NYSE:QGEN) Q3 expected to be more than $0.62 vs $0.64 Est. sees Q3 sales of $538.330 millio

Qiagen N.V. (QGEN) Q2 2026 Earnings Call Transcript

Qiagen (QGEN) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estim

While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed

Qiagen (NYSE:QGEN) FY2026 expected to be more than $2.43 vs $2.42 Est. affirms FY2026 sales outlook

Qiagen (NYSE:QGEN) reported quarterly earnings of $0.62 per share which beat the analyst consensus e

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Stan

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings

Allspring Global Investments Holdings LLC lessened its holdings in shares of Qiagen N.V. (NYSE: QGEN

More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked

GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; F

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Fr

Qiagen N.V. is rated a Buy, supported by new product launches and automation initiatives poised to d

Private equity giants circle Qiagen (QGEN) with potential bids of $50/share. Get the details on the

Qiagen is ​drawing ‌early takeover interest ​from ​buyout firms, ⁠including ​EQT AB , ​Advent and KK

Qiagen N.V. (QGEN) Shareholder/Analyst Call Transcript

Morgan Stanley analyst Steve Beuchaw upgrades Qiagen (NYSE:QGEN) from Equal-Weight to Overweight

Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcui

QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) announced at the 2026 BIO-IT World Conference &a

Stifel analyst Daniel Arias maintains Qiagen (NYSE:QGEN) with a Hold and lowers the price target

Co-founder and former CEO Dr. Metin Colpan to become Honorary Chairman of the Supervisory Board afte

TD Cowen analyst Dan Brennan maintains Qiagen (NYSE:QGEN) with a Hold and lowers the price target

Ambition to support high-throughput laboratories in efficiently scaling latent tuberculosis (TB) scr

Qiagen (NYSE:QGEN) FY2026 expected to be more than $2.43 vs $2.51 Est. affirms FY2026 sales outlook

JP Morgan analyst Casey Woodring maintains Qiagen (NYSE:QGEN) with a Overweight and lowers the pr

Citigroup analyst Patrick Donnelly maintains Qiagen (NYSE:QGEN) with a Neutral and lowers the pri

Barclays analyst Luke Sergott maintains Qiagen (NYSE:QGEN) with a Equal-Weight and lowers the pri

Analysts upgraded Qiagen, Armstrong World, T-Mobile, Crane Co, and Centene Corp stocks, with price t

Analysts change outlook & ratings for QGEN, AWI, CR, ATEN, PLUG, SBUX, CECO, CNC. Price targets

Baird analyst Catherine Schulte upgrades Qiagen (NYSE:QGEN) from Neutral to Outperform and lowers

Tech stocks slide as OpenAI's user growth miss reignites AI capex skepticism, while oil rallies

Barclays analyst Luke Sergott downgrades Qiagen (NYSE:QGEN) from Overweight to Equal-Weight and a

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced newly published clinical and